TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Minerva Neurosciences ( (NERV) ) has shared an update.
On November 14, 2025, Minerva Neurosciences appointed Dr. Inderjit Kaul to its Board of Directors as part of an expansion following a securities purchase agreement. Dr. Kaul, who brings extensive experience in drug development, will also serve as a consultant to assist with the clinical development of roluperidone, a treatment for negative symptoms of schizophrenia. This appointment aligns with Minerva’s recent $200 million fundraising effort to support a Phase 3 trial of roluperidone, aiming to address a significant unmet need in schizophrenia treatment.
The most recent analyst rating on (NERV) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.
Spark’s Take on NERV Stock
According to Spark, TipRanks’ AI Analyst, NERV is a Underperform.
The overall stock score for Minerva Neurosciences is driven by significant financial instability, marked by negative equity and a lack of revenue. While the valuation suggests potential undervaluation, the financial risks present significant concerns. Technical indicators show some short-term positivity, but long-term trends are not favorable. The absence of earnings call and corporate events data means these factors do not influence the score.
To see Spark’s full report on NERV stock, click here.
More about Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.
Average Trading Volume: 2,958,259
Technical Sentiment Signal: Hold
Current Market Cap: $30.49M
For a thorough assessment of NERV stock, go to TipRanks’ Stock Analysis page.